Dose adjustment of entacapone/cordan in special populations

Oral preparations of Entacapone are often used in combination with levodopa/benserazide or levodopa/carbidopa to improve symptom fluctuations in patients with Parkinson's disease. The usual adult dose is 200 mg administered daily with levodopa, with the maximum daily dose not to exceed 2000 mg. However, for special populations, such as the elderly and those with renal or hepatic impairment, dose adjustment and medication monitoring are crucial.

Elderly patients are usually accompanied by decreased renal function or multiple comorbidities. When using entacapone, they should start with a lower dose, gradually adjust to the standard dose, and closely observe motor symptoms and drug tolerance. Patients with renal insufficiency may experience prolonged drug plasma concentrations, requiring extended dosing intervals or reduced daily doses. People with hepatic impairment also need to be cautious, because the metabolism of entacapone mainly depends on the liver, and patients with liver impairment may be at increased risk of adverse drug reactions, including nausea, diarrhea, or fluctuations in motor symptoms.

In addition, patients with cardiovascular disease or cognitive dysfunction need to monitor heart rate, blood pressure and cognitive status when adjusting the dose to prevent the drug from affecting their daily activities. Dose adjustment for special populations not only involves the drug itself, but also should be combined with the dose and duration of use of levodopa to ensure optimal combined efficacy. Overseas guidelines emphasize that through individualized adjustments, gradual progress and close follow-up, the risk of adverse reactions can be effectively reduced while ensuring the stability of patients' movement and life functions.

In general, entacapone emphasizes scientific individualization, combination drug optimization and long-term dynamic monitoring in the dosage management of special populations. By rationally adjusting the dose and observing the efficacy, patients can not only obtain stable motor control, but also reduce medication risks and achieve safe and effective long-term management of Parkinson's disease.

Reference materials:https://www.drugs.com/mtm/comtan.html